Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Cellular heterogeneity is a hallmark of human neuroblastoma tumors and cell lines. Within a single neuroblastoma are cells from distinct neural crest lineages whose relative abundance is significant for prognosis. We postulate that a self-renewing multipotent tumor stem cell, which gives rise to diverse cell lineages, is the malignant progenitor of this cancer. To test this hypothesis, we have established 22 cloned, phenotypically homogeneous populations of the three major cell types from 17 neuroblastoma cell lines. In vitro, malignant neuroblastoma stem cells, termed I-type (intermediate type), have distinct morphologic, biochemical, differentiative, and tumorigenic properties. I-type cells express features of both neuroblastic (N) cells (scant cytoplasm, neuritic processes, neurofilaments, pseudoganglia, and granin and neurotransmitter enzyme expression) and substrate-adherent (S) cells (extensive cytoplasm and vimentin and CD44 expression). Moreover, they show bidirectional differentiation to either N or S cells when induced by specific agents. I-type cells are significantly more malignant than N- or S-type cells, with four- to five-fold greater plating efficiencies in soft agar and six-fold higher tumorigenicity in athymic mice. Differences in malignant potential are unrelated to N-myc amplification/overexpression or the ability to digest and migrate through the extracellular matrix. Immunocytochemical analyses of a small series of tumors reveal that frequency of cells coexpressing N and S cell markers correlates with poor prognosis. Thus, I-type stem cells may be instrumental in the genesis and growth of tumors in the patient. Their unique biology deserves attention and further investigation.
Walton
Jeanette D
JD
Laboratory of Neurobiology, Department of Biological Sciences, Fordham University, Bronx, NY 10458, USA.
Kattan
David R
DR
Thomas
Sharon K
SK
Spengler
Barbara A
BA
Guo
Hong-Fen
HF
Biedler
June L
JL
Cheung
Nai-Kong V
NK
Ross
Robert A
RA
D000818:Animals; D015153:Blotting, Western; D002454:Cell Differentiation / Q000502:physiology; D045744:Cell Line, Tumor / Q000473:pathology*; D019070:Cell Lineage; D002465:Cell Movement / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D009423:Nervous System Neoplasms / Q000503:physiopathology*; D009447:Neuroblastoma / Q000503:physiopathology*; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013234:Stem Cells / Q000473:pathology* / Q000502:physiology*
D016271:Proto-Oncogene Proteins c-myc
Oncology (Williston Park). 1997 Dec;11(12):1857-66; discussion 1869-72, 1875
9436190
J Biol Chem. 2004 Jul 2;279(27):27994-9
15117961
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5
11121071
Prog Clin Biol Res. 1994;385:261-7
7972218
Cancer Res. 1989 Jan 1;49(1):219-25
2535691
Mol Cell Biol. 1991 Mar;11(3):1360-71
1996098
Oncogene. 2000 Jan 20;19(3):380-6
10656685
Pediatr Clin North Am. 1997 Aug;44(4):919-37
9286292
Prog Clin Biol Res. 1988;271:291-306
3406003
Oncol Res. 1997;9(9):467-76
9495452
Cancer Genet Cytogenet. 1999 Jul 15;112(2):124-9
10686938
Oncogene. 1999 Apr 29;18(17):2703-10
10348344
Nat Rev Cancer. 2003 Mar;3(3):203-16
12612655
Nature. 2001 Nov 1;414(6859):105-11
11689955
Proc Natl Acad Sci U S A. 1986 Aug;83(16):5929-33
2426708
Arch Med Res. 2003 Nov-Dec;34(6):461-75
14734086
Cancer Lett. 2003 Jul 18;197(1-2):35-9
12880957
Cancer Res. 1987 Jun 15;47(12):3239-45
2438036
Oncogene. 1996 Aug 15;13(4):803-12
8761302
Development. 2003 Jan;130(2):321-30
12466199
Cancer. 2001 Nov 1;92(9):2451-61
11745303
Cancer Res. 2001 Sep 15;61(18):6892-8
11559566
Cancer. 1993 Dec 1;72(11):3346-54
8242562
Cell Growth Differ. 1995 Apr;6(4):449-56
7794812
Cancer Res. 1987 Mar 1;47(5):1383-9
3028608
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83
14645703